Edison Investment Research - Ossur hf. (OSSR) QuickView: Dual-track growth strategy paying off

Report

Edison Investment Research

QuickView: Dual-track growth strategy paying off

Ã–ssur produced a solid Q3 result, suggesting that its dual-growth strategy in prosthetics and bracing & support is paying off. Rapid sales growth of high-priced bionic prostheses contributed to the upgrade of the groupâ€™s financial guidance for the year. Ã–ssur trades at 20.7x 2014e P/E vs a 6% and 17% premium to Smith & Nephew and its US ortho peers, respectively.

31/10/2014 2 EN

Underlying

Ossur hf.

Ossur is an orthopaedics solutions group based in Iceland. Co. specializes in the manufacture and sale of high quality orthopaedic solutions. Co. is engaged in the development and manufacturing of products in three categories: Bracing and Support (products are primarily used to support joints and other body parts, both for therapeutic and preventive purposes); Prosthetics (products include artificial limbs and related products for individuals without limbs or with limbs amputated); and Compression Therapies (treatment for venous ulcers and edema). Co.'s product line includes brands: RHEO KNEE®, POWER KNEE™ and PROPRIO FOOT®. Co. orthopaedic market includes the Americas, EMEA and Asia.

See profile

IS0000000040 Nasdaq Nordic Copenhagen Iceland

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

DnB Markets

Embla Medical (Buy, TP: DKK39.00) - Q1 set to build momentum

We expect Embla Medical (formerly Ossur) to report another solid organic growth quarter, despite tough comparables and Easter effects. We forecast the bionics portfolio to continue to drive prosthetics growth, with more muted growth in Bracing and Support and Patient Care. While we expect the EBIT margin to expand YOY in Q1, and continue to build throughout 2024, we estimate previously taken cost savings to have less effect in the quarter. We reiterate our BUY and DKK39 target price.

Free Trial

April 12, 2024 April 12, 2024 1 EN

DnB Markets

Ossur (Buy, TP: DKK39.00) - Mixed Q4, supportive 2024 guidance

The Q4 results were mixed, with a comfortable beat on organic growth but below-consensus margins. The 2024 guidance was above consensus for organic growth and the EBITDA margin. We still like Ossur, and reiterate our BUY and DKK39 target price.

Free Trial

January 31, 2024 January 31, 2024 1 EN

DnB Markets

Ossur (Buy, TP: DKK39.00) - Q4e another solid quarter

In line with consensus, we expect Q4 to mark a solid end to 2023, driven by strong prosthetics growth and more muted growth for the rest of the business. We expect a strong Q4 EBITDA margin, finishing the year at a high of c20%. We expect more clarity on the proposed Medicare reimbursement changes with the Q4 results (due at 08:00 CET on 30 January) and estimate that the changes could more than double the US bionic knee market over time. We reiterate our BUY and DKK39 target price.

Free Trial

January 23, 2024 January 23, 2024 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

23h / 24m 23h / 24m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Dual-track growth strategy paying off

Embla Medical (Buy, TP: DKK39.00) - Q1 set to build momentum

Ossur (Buy, TP: DKK39.00) - Mixed Q4, supportive 2024 guidance

Ossur (Buy, TP: DKK39.00) - Q4e another solid quarter

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe